Dublin, Ireland March 5 2024

Innovation Zed, a leading Irish R&D company specialising in innovative medical devices, announces its strategic partnership with Enhance-D, a Swiss company dedicated to enhancing diabetes and exercise management through its digital health platform. This collaboration represents a significant leap forward in utilising digital solutions to optimise diabetes therapy and patient outcomes.

Enhance-D, a pioneering force in diabetes management, offers a comprehensive platform designed to empower individuals living with diabetes. By leveraging cutting-edge technologies and personalised solutions, Enhance-D’s mission is to transform how diabetes is managed around exercise, providing patients with the tools and support they need to lead healthier lives.

Through this partnership, Innovation Zed’s DOSE™ technology can seamlessly integrate into Enhance-D’s platform. Innovation Zed’s third-generation technology DOSE™ (trademarked InsulCheck for the diabetes market) captures and stores insulin injection data, empowering MDI (multiple daily injections) users. “We are very happy to collaborate with the team behind Enhance-D and advance our shared commitment to improve diabetes management,”, said Dr Dean Minnock, CEO of Innovation Zed. “By integrating our InsulCheck DOSE™ technology into Enhance-D’s innovative platform, we aim to empower users and their caregivers with real-time data and personalised support around exercise, ultimately improving their quality of life.”

Enhance-D’s dedication to redefining diabetes care aligns seamlessly with Innovation Zed’s vision of leveraging technology to enhance patient outcomes. “This partnership with Innovation Zed represents a significant moment for us at Enhance-D. It’s more than just a collaboration; it’s a shared vision to revolutionise diabetes management around exercise by harnessing the power of integrated technologies. Through our combined efforts, we are working for a future where managing exercise and diabetes is more intuitive, efficient, and aligned with our users’ lifestyles.” remarked Federico Fontana, CEO at Enhance-D. This partnership marks a significant milestone in the evolution of diabetes care, highlighting the transformative potential of integrated technologies in addressing the complex challenges associated with chronic diseases. Innovation Zed and Enhance-D remain committed to improving the lives of individuals living with diabetes and look forward to the positive impact of this collaboration.

ABOUT ENHANCE-D Enhance-D is a pioneering company that revolutionises diabetes management around exercise through innovative technologies and personalised solutions. Committed to empowering individuals living with diabetes, Enhance-D offers a comprehensive platform that integrates advanced medical devices with digital therapeutics and personalised care, enabling patients to take control of their health journey. Learn more at www.enhance-d.com.

ABOUT INNOVATION ZED Innovation Zed is a leading provider of connected health solutions, specialising in developing innovative medical devices to support drug adherence and diabetes management. With a focus on leveraging technology to enhance patient outcomes, Innovation Zed continues to pioneer new methods for personalised condition management and improved drug adherence. Visit www.innovationzed.com to learn more.

Dubai, United Arab Emirates, 11th April 2023

Innovation Zed, an Irish R&D company specializing in the design and development of innovative medical devices has partnered with GluCare.Health, a leading metabolic disease management platform, to provide connected insulin pen technology as part of a combination product in GluCare.Health’s digital clinic ecosystem. The partnership will open the door to personalised therapy and compliance insights for various drug delivery devices, including injection pens used for a range of drug therapies.

Innovation Zed’s medical device technologies include a range of smart add-on devices that can automatically log injection data and store vital injection history for Multiple Daily Injection (MDI) users. Marketed under the InsulCheck brand, these products capture valuable injection data such as the timestamp of injection events, dose dialled and temperature. By integrating these technologies, GluCare.Health is better positioned to support its insulin-dependent patients with real-time feedback of insulin doses and timings. This enables the company to build a more comprehensive picture of patients’ health status and needs.

Dr. Dean Minnock, CEO at Innovation Zed, expressed his excitement about the partnership, saying, “Having developed our technologies with the initial focus of insulin therapy for diabetes, we have created a product that we have long believed would be extremely beneficial to any person requiring multiple daily injections. This opportunity from GluCare.Health to adapt and apply our InsulCheck technologies to new injection pens allows us to support therapy requirements and will see Innovation Zed now leap into new markets and most importantly support new audiences.”

The partnership is also expected to improve adherence to injection therapy, one of the most challenging aspects of any MDI therapy. By motivating people to increase adherence to their daily injection schedule, this collaboration has the potential to improve therapy response and overall outcomes.

Dr. Ihsan Almarzooqi, Co-Founder and Managing Director of GluCare.Health, said, “Our model of continuous care has shown to be vastly better than the episodic care practiced by traditional care providers. This partnership is a significant step forward in our mission to close the loop for insulin-dependent diabetics and obtain new data points previously blind to healthcare providers such as insulin timing, doses and temperature. Along with our engagement and meta[bolic] scores, we will be able to further personalize treatment and manage compliance under our clinic-in-the cloud model for multi dose insulin (MDI) patients.”

The partnership between Innovation Zed and GluCare.Health represents a significant milestone in the management of diabetes, and both companies look forward to the positive impact this collaboration will have on the lives of people living with diabetes.

ABOUT GLUCARE.HEALTH

The first hybrid Digital Therapeutics (DTx)+ Human vertically integrated diabetes platform of its kind, GluCare.Health is reinventing metabolic care and transforming lives. Conceptualized in the UAE and opening the doors to its state-of-the-art 10,000 sq foot Dubai clinic in September 2020, it is the world’s first healthcare provider to empower both clinicians and patients through Continuous Metabolic Monitoring as part of its standard model of care, an innovative and highly personalized ‘continuous healthcare’ approach that provides a comprehensive and real-time view of patients.  As part of its unique model, GluCare.Health is also an early adopter of – and the region’s first clinic to use – Digital Therapeutics (DTx), combining it with wearable, data analytics, unique in-clinic workflows, and a caring and connected expert care team. Applying technology as a humanizing force, GluCare.Health’s team partners with patients and their families, giving them the tools, knowledge, and continuous support to live longer, healthier, and more fulfilling lives. https://glucare.health/

Dublin, Ireland February 20, 2023

Innovation Zed, an Irish R&D company specialising in the design, development and manufacturing of medical technologies, announced today it has secured a CE Mark for the InsulCheck DOSE add-on device. As a leader in connected and smart drug delivery technologies, this certification showcases our commitment to meeting relevant health, safety, and environmental requirements regarding consumer safety in the European Union (EU). It also opens the door for commercial expansion within Europe for the growing company.

InsulCheck DOSE is a single-unit add-on device for pen injectors that automatically captures dose value dialled, injection event time stamp and temperature as well as mounting and unmounting events. With InsulCheck DOSE, real-time injection event data are logged and sent automatically to a compatible display device. Product highlights include:

• A discreet add-on device compatible with all pen-injectors
• Captures dose dialled, timestamp, ambient temperature, etc.
• A convenient device with no buttons, no calibration requirements or interference with the normal injection process
• Increased user engagement through high-quality usability support features from a vibrant OLED screen

Innovation Zed is dedicated to helping insulin pen users within the diabetes population. Given our understanding of the challenges faced by insulin pen users worldwide, our focus is to support all insulin pen users regardless of their injection pen of choice. As a result of a collaboration with our partner SHL Medical and its subsidiary SHL Technologies, InsulCheck DOSE has been developed to meet the compatibility challenges presented by various injection pen designs and in particular the difficulties in working on a technology to reliably and accurately support low-cost disposable pens.

Dr Dean Minnock, CEO of Innovation Zed said “InsulCheck DOSE is a third-generation product of the InsulCheck family and the most intelligent and compatible evolution of the InsulCheck platform. InsulCheck DOSE provides data that, when applied correctly, facilitates an evidence-driven approach to precision insulin management and significantly helps people with diabetes make more informed choices for their personal therapy plan. Our InsulCheck DOSE supports all insulin pens without changing the usability of the pen in any way and without interfering in the normal injection process. In securing the CE mark for InsulCheck DOSE we reached an incredible milestone for our company and for people living with diabetes in Europe.”

Innovation Zed expects to initiate a commercial launch of InsulCheck DOSE in Europe during 2023. The company also has plans to introduce bespoke variations of InsulCheck DOSE to new injection devices for various drug therapies over the coming years.

Dublin, Ireland May 30, 2022

Innovation Zed, an Irish MedTech R&D company, today announced the signing of a global partnership and data integration agreement for its family of insulin pen ‘add-on’ devices with SNAQ.

SNAQ supports people living with diabetes to take the guesswork out of mealtime decisions. The award-winning app helps to count the carbs, protein, and fat content of meals by snapping a photo and supports learning what keeps glucose levels in target range after meals. SNAQ connects to many popular diabetes devices and apps.

Innovation Zed, headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin (UCD), is dedicated to helping insulin pen users within the diabetes population.

Currently, adherence to insulin therapy is one of the most difficult aspects of diabetes treatment. A focus on motivating people to increase adherence to their daily injection schedule can potentially improve their time in range (TIR) and overall long-term glucose control (HbA1c). Such improvements can assist in reducing the likelihood of developing diabetes related complications.

As a result of this new agreement SNAQ and Innovation Zed will pursue joint efforts in order to integrate and promote their respective products.

“Through the upcoming integration of our BLE enabled InsulCheck products “InsulCheck CONNECT” and “InsulCheck DOSE” with the SNAQ App, we can empower existing SNAQ users, and entice new users to adopt this technology with the aim of improving glucose control around meals” said Dean Minnock, CEO, Innovation Zed. ”Our products are designed to enable these improvements by automatically capturing insulin doses and, when combined with a solution such as  SNAQ, make optimum therapy attainable.”

Aurelian Briner, CEO of SNAQ, said,

“Although actively requested by people living with diabetes, it is often still complicated or even impossible to connect data from different diabetes devices. Through this partnership we help to automatically import and connect insulin data with meals. We are very excited about the next steps of making mealtime decisions less guesswork for people living with diabetes.”

Innovation Zed’s add-on technologies InsulCheck CONNECT and InsulCheck DOSE are BLE enabled technologies for insulin pen users to assist tracking and providing insulin pen data to be shared with diabetes management applications to improve outcomes and remove burdens of injection regimes. InsulCheck CONNECT automatically collects essential usage data that informs insulin pen users of their injection history. When paired with a Bluetooth® enabled device, the end-user can view behavioural analysis on their choice of diabetes management applications. InsulCheck DOSE is a single unit add-on device for pen injectors that automatically captures dose value dialled, injection event timestamp, temperature and mounting/unmounting data.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Innovation Zed is under license. Other trademarks and trade names are those of their respective owners.

Dublin, Ireland November 15, 2021

Innovation Zed, developer of novel diabetes management technologies (the InsulCheck range), headquartered at NovaUCD, at University College Dublin, Ireland are delighted to announce today the arrival of the much anticipated InsulCheck DOSE technology that will be coming to market in 2022.

“It is with great excitement that we announce the arrival of our InsulCheck DOSE by Innovation Zed. As the third generation product of the InsulCheck family, this technology has been a dream of our company from its very inception and this product is the culmination of over a decade of work to support multiple daily injection (MDI) pen users. We understood the difficult challenges presented by various injection pens and in particular the difficulties in working on a technology to reliably and accurately support low-cost disposable pens. This is the reason we at Innovation Zed took an incremental approach to developing the InsulCheck DOSE product.” – said Dr Dean Minnock, CEO at Innovation Zed. “We have taken a unique approach in developing this technology by working closely with users, caregivers, software developers, medical device specialists and previous generations of InsulCheck products to design and develop a product that bolsters and supports the needs of all stakeholders” – he continued.

Innovation Zed has collaborated with SHL Medical in the development of InsulCheck DOSE. SHL Medical is a world-leading provider of drug delivery solutions and also offers design-to-build and contract manufacturing services for various medical products through its subsidiary, SHL Technologies.

WHAT IS INSULCHECK DOSE?

InsulCheck DOSE is a single unit add-on device for pen injectors that automatically captures dose value dialled, injection event time stamp, temperature and mounting/unmounting events. Through Bluetooth^® Low Energy (BLE) technology, InsulCheck DOSE transmits these data points to a paired companion software platform in real time for inclusion in diabetes management therapy.

“InsulCheck DOSE technology supports MDI users by enhancing their traditional injection pen and transforming it into a smart pen that can optimise their treatment and reduce the stresses caused by MDI therapy. Through this technology we are enabling every MDI user to make their existing injection pen a smart pen without having to compromise or change from their existing HMO or health service provider” – said Dr Minnock.

INSULCHECK DOSE FEATURES

The technology utilises a multi-sensor approach to accurately detect and register the actual dosage dialled and provide an injection event time stamp to log the event. The incorporated temperature sensors constantly monitor the ambient temperature of the area surrounding the injection pen, providing safety notifications to the user if the surrounding temperature may affect the drug housed inside the pen. Using an OLED display, InsulCheck DOSE provides visual information and feedback to the user, helping improve best practice procedures. A rechargeable lithium battery powers the DOSE device and is capable of operating well over 1 week at a time between charges. As a BLE enabled product, all data captured by InsulCheck DOSE is transferred in real time to a paired mobile application. If the user does not wish or is unable to remain connected with a companion software platform, InsulCheck DOSE has built-in memory to store over 40 days’ worth of injection history at a time. Through modification of the sleeve component and firmware refinement, InsulCheck DOSE can become applicable to all injection pens for various drug treatments. At launch, it will support a range of reusable and disposable injection pens on the insulin market from Novo Nordisk, Lilly and Sanofi.

“Our ability to learn, adapt and improve our technology is one of the key aspects of InsulCheck DOSE and one that separates us greatly from our competitors. The future-proof design of InsulCheck DOSE means that it can be adapted to support the various pen mechanisms in use today, whilst maintaining accuracy and reliability for the patient. Among the numerous unique features of this product is the built in Firmware Over The Air (FOTA) capability which allows continuous optimisation of the device’s firmware even when deployed in the field. That future-proofing allows InsulCheck DOSE to adapt to physical injection pen variations from the pen manufacturers and improve on device performance ‘on the go’ from real world user behaviours” – said Dr Minnock.

VALUE PROPOSITION

The InsulCheck DOSE device helps patients, automatically track their daily injection and monitor treatment adherence. The intended use of InsulCheck DOSE is as a supporting component in a management ecosystem for therapy optimisation, remote monitoring and enhanced connected care. Dr Minnock explained,

“InsulCheck DOSE is a disruptive technology that will revolutionise an entire market and change the lives of millions of MDI users worldwide. Innovation Zed have entered into discussions with market leaders in the diabetes management sector with the intention of finding a strategic global partner in taking this InsulCheck DOSE technology to the market. InsulCheck DOSE is an attractive offering to any organisation working in this space as it can significantly enhance their existing offering to become more competitive and command new growth and additional market share.”

CONCLUSION

InsulCheck DOSE enters production at the end of Q2 2022 and will be available as an FDA registered and CE marked product. Manufacturing of InsulCheck DOSE will be handled by Innovation Zed’s existing manufacturing partner SHL Technologies, a subsidiary of SHL Medical. If you wish to understand InsulCheck DOSE or any of our technology offerings in greater detail, please feel free to visit our website or reach out to us directly.

The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Innovation Zed is under license. Other trademarks and trade names are those of their respective owners.

Dublin, Ireland October 11, 2021

Innovation Zed Ltd., developer of novel diabetes technologies (the InsulCheck range), announced further advancement in their research of technologies for non-invasive Continuous Glucose Monitoring and a new researcher to this project, Dr Rui Wu.

Innovation Zed, headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin, who develop technologies to improve the health and quality of life for individuals living with diabetes, has taken another leap forward in the development of a non-invasive glucometer.

Innovation Zed has collaborated with the Irish Research Council (IRC) and University College Dublin (UCD) in advancing their research into non-invasive Continuous Glucose Monitoring (CGM) systems. As a result of this collaboration, Innovation will build on previous work with both the IRC and UCD in advancing a non-invasive multi-sensor approach to recording acute changes in the blood glucose levels of individuals living with diabetes.

“We are delighted to advance our research into a non-invasive CGM system,” said Dr Dean Minnock, CEO, Innovation Zed. “We pride ourselves on taking on the complex technological challenges with our sole aim of easing the stresses caused by diabetes, and this project is no different.” The monitoring of glucose fluctuations is a vital aspect for acute control and improved long-term health outcomes, making it a significant component in the daily life of people with diabetes. Currently, commercial Blood Glucose Meters require a finger prick whilst Continuous Glucose Meters require the insertion of a filament underneath the skin, resulting in small wounds that can be the cause of pain and infections. “There is a clear need for alternative options that are non-invasive, painless, discreet and easy to use, and this is a further step in the right direction,” he continued.

Innovation Zed has already brought to market various technologies to support multiple daily injection (MDI) insulin users with add-on technology that automatically collects essential usage data. Available under the “InsulCheck” brand, these technologies are designed to inform insulin pen users of their injection history and trends.

“We have tremendous experience in designing and developing best-in-class, patient-centred products with the desire of leaving no patient behind when it comes to supporting them. Our partnership with SHL Medical has been instrumental in our ability to design, develop and bring to market these solutions,” said Dr Minnock.

Dr Rui Wu has joined this project as the lead researcher and will be bringing extensive subject knowledge and new focus to the project.

“I am delighted to be involved in this project and to be working with Innovation Zed on this fascinating project,” said Dr Wu. Dr Wu has recently completed a postdoctoral research post at UCD and is supported in this project by Prof Madeleine Lowery, Head of Biomedical Engineering at UCD.

“This non-invasive glucometer project is the latest addition to several exciting projects here at Innovation Zed,” said Dr Minnock. “This is also the first of many fascinating announcements we will be making over the next 12 months. Our strategy of bringing cutting-edge diabetes management technologies to a wider audience is advancing strongly, and we are constantly improving on our portfolio of offerings”.

Dublin, Ireland, and Barcelona, Spain 15^th July 2021

Innovation Zed Ltd., the developer of novel Insulin Pen “InsulCheck CONNECT” add-on device, and SocialDiabetes, a leading diabetes management company, today announced the signing of a global partnership and data integration agreement.

As a result of this new partnership the companies will pursue joint efforts to promote and sell their products as a single integrated system to improve health outcomes for people with diabetes. Innovation Zed is headquartered at NovaUCD, the Centre for New Ventures and Entrepreneurs at University College Dublin. SocialDiabetes is one of the most established Diabetes management software providers who are headquartered in Barcelona, Spain.

Innovation Zed, launched InsulCheck CONNECT, an insulin pen add-on technology which automatically collects essential usage data that informs insulin pen users of their injection history. When paired with the SocialDiabetes management platform via Bluetooth^®, both the end-user and physician can record and view behavioural data to improve diabetes management.

Currently, adherence to insulin therapy is one of the most difficult aspects of diabetes treatment. A simple focus on motivating users to increase adherence to their daily injection schedule can potentially improve their long-term glucose control (HbA1c). Such improvements can assist in reducing the likelihood of developing diabetes related complications.

 “Now that our InsulCheck CONNECT technology is integrated with the SocialDiabetes Platform, we can empower existing platform users, and entice new users to adopt this closed data system ecosystem with aims to improve adherence and their diabetes treatment,” said Dr Dean Minnock, CEO, Innovation Zed.

María Jesús Salido, CEO, SocialDiabetes, said,

“This global partnership is yet another cornerstone in our strategy to bring quality diabetes management to a wider audience. Therapy adherence is a serious issue and we are dedicated to making a cumbersome task as easy as it could be. The unique features for insulin pen users in SocialDiabetes are designed to both save time and allow them to do things, otherwise only available to pump users.”

“We believe the option to calculate and set reminders for split extended bolus and the automated processes that a Bluetooth^®connected pen allows will be of great benefit to owners of Innovation Zed’s InsulCheck Connect.”